Waiting to Exhale: Lilly Inhaled Insulin NDA Filing Will Wait For Safety Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III AIR safety study, which recently completed enrollment, will last 24 months.
You may also be interested in...
Lilly/Daiichi On Track For Prasugrel NDA By Year End, Despite Mixed Results
Benefits of the anticlotting drug “clearly outweigh the risks” for most patients, Lilly’s Paul says at R&D day.
Lilly/Daiichi On Track For Prasugrel NDA By Year End, Despite Mixed Results
Benefits of the anticlotting drug “clearly outweigh the risks” for most patients, Lilly’s Paul says at R&D day.
Lilly/Alkermes Broaden Inhaled Insulin Manufacturing Agreement
The update ensures adequate supplies of insulin powder “if and when” the AIR inhaled insulin system is launched, Lilly told “The Pink Sheet” DAILY.